Cross-institution positioning
May 15, 2026Strong institutional reduction. 1 exited across 1 comparable institution.
Source: Schedule 13 researchACRV Institutional Ownership
Acrivon Therapeutics, Inc.
Latest stored close $1.87 as of Oct 8, 2026 View live quote ↗
STOCKNODE Outlook
Neutral
37/100
1 tracked · 1 comparable
Latest filing
May 15, 2026
Positive breadth
0 positive · 1 negative
Recent close
$1.87
Research confidence
Limited
Institutional Research 18/100 · 0 accumulating · 1 reducing / exited
Ownership history
Reported ownership % history
Latest filing May 15, 2026
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
Locked preview
Unlock the reported ownership timeline
Unlock full research
Accumulating0
Newly reported0
Reducing / exited
1
52-week position
—
Institutional Intelligence
Why STOCKNODE says Neutral
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
STOCKNODE Outlook
Neutral 37/100
Confidence:Limited
Why this signal
- 0 tracked institutions accumulating versus 1 reducing/exited.
- Latest comparable Form 13F activity is net positive across tracked managers.
Institutional
34/100
Insiders
22/100
Fundamentals
59/100
Events
50/100
Quarterly 13F activity
Jun 30, 20261 increased/new, 0 reduced/exited, and 1 unchanged across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsInsider filing activity
Oct 5, 2026Over the last 90 days, SEC-coded non-derivative P/S activity includes 0 purchases by 0 reporting owners and 10 sales by 7 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/5Material company events
Aug 12, 20262 non-amendment material events in the last 90 days; 1 capital-related filing/event (1 equity-related, 0 debt-related); Latest classified evidence: Employee-plan securities registration. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataSEC fundamentals
Aug 12, 2026Net income +14.5% YoY; Free cash flow +3.3% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsPrice context
Sep 15, 2026Recent close is 24% through its reported 52-week range; +21.2% over one year.
Source: Stored historical price series
Latest filing decision brief
Investor / Pro
Research the latest Schedule 13G amendment from Citadel Advisors.
Filed May 15, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
Supporting institutional evidence
Institutional Evidence
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
Latest filing
May 15, 2026
Latest reported position changes
Investor / Pro detailSee each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Citadel Advisors
Filed May 15, 2026
Direction locked
Unlock the actual direction, share change, ownership change, and classification basis.
No premium position values are sent in this locked preview.
Unlock full research
Reported direction breadth by as-of date
Locked previewComparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Unlock actual accumulation vs. reduction breadth across reported position dates.
View plans
Institution comparison
Investor / Pro detailCompare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Citadel Advisors
Filed May 15, 2026
Unlock the evidence behind the score
Know who changed position, by how much, and when the SEC learned about it.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
✓ Actual share and ownership changes
✓ Position as-of date vs. SEC filed date
✓ Deterministic direction basis
✓ Full evidence on every eligible stock
SEC Forms 3, 4 & 5
Insider activity
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
30-day purchases00 reporting owner(s)
30-day sales11 reporting owner(s)
90-day purchase breadth0
90-day sale breadth7Multi-insider
View recent insider filing evidence
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Miller Mary | SOpen-market or private sale | Common Stock | 294 | $1.99 | Direct | Oct 7, 2026 |
| Aug 31, 2026 | Levin Michaela | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 130.0K | $0.00 | Direct | Sep 2, 2026 |
| Aug 31, 2026 | Levin Michaela | AGrant, award, or other acquisition | Common Stock | 30.0K | $0.00 | Direct | Sep 2, 2026 |
| Aug 25, 2026 | Blume-Jensen Peter, Masson Kristina | SOpen-market or private sale | Common Stock | 14.0K | $2.21 | Direct | Aug 27, 2026 |
| Aug 18, 2026 | Blume-Jensen Peter, Masson Kristina | SOpen-market or private sale | Common Stock | 484 | $2.01 | Indirect | Aug 20, 2026 |
| Aug 18, 2026 | Blume-Jensen Peter, Masson Kristina | SOpen-market or private sale | Common Stock | 1.2K | $2.01 | Direct | Aug 20, 2026 |
| Aug 18, 2026 | Devroe Eric | SOpen-market or private sale | Common Stock | 604 | $2.01 | Direct | Aug 20, 2026 |
| Aug 18, 2026 | Gamelin Erick | SOpen-market or private sale | Common Stock | 400 | $2.01 | Direct | Aug 20, 2026 |
| Aug 18, 2026 | Miller Mary | SOpen-market or private sale | Common Stock | 185 | $2.01 | Direct | Aug 20, 2026 |
| Aug 18, 2026 | Peterson Katharine | SOpen-market or private sale | Common Stock | 101 | $2.01 | Direct | Aug 20, 2026 |
| Aug 4, 2026 | Levy Adam D. | SOpen-market or private sale | Common Stock | 1.1K | $1.57 | Direct | Aug 6, 2026 |
| Jul 21, 2026 | Miller Mary | SOpen-market or private sale | Common Stock | 573 | $1.76 | Direct | Jul 23, 2026 |
| Jun 17, 2026 | RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M. | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 20.3K | $0.00 | Indirect | Jun 22, 2026 |
| Jun 17, 2026 | TOMSICEK MICHAEL JOHN | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 20.3K | $0.00 | Direct | Jun 22, 2026 |
| Jun 17, 2026 | Shacham Sharon | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 20.3K | $0.00 | Direct | Jun 22, 2026 |
| Jun 17, 2026 | Palani Santhosh | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 20.3K | $0.00 | Direct | Jun 22, 2026 |
| Jun 17, 2026 | Magovcevic-Liebisch Ivana | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 20.3K | $0.00 | Direct | Jun 22, 2026 |
| Jun 17, 2026 | DiRocco Derek | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 20.3K | $0.00 | Direct | Jun 22, 2026 |
| Jun 17, 2026 | BAUM CHARLES M | AGrant, award, or other acquisition · derivative | Stock Option (Right to Buy) | 20.3K | $0.00 | Direct | Jun 22, 2026 |
| May 21, 2026 | Blume-Jensen Peter, Masson Kristina | FTax/price withholding or payment | Common Stock | 13.7K | $1.79 | Direct | May 26, 2026 |
SEC company-event context
Material company events
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
30-day material events0
90-day capital-related1
90-day equity-related1
90-day debt-related0
View recent company-event filing evidence
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Aug 12, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Aug 12, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jun 17, 2026 | 8-K | 5.02, 5.07, 9.01 | Director or executive change; Shareholder vote results; Financial statements / exhibits | — | Filing |
| May 13, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Mar 19, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Mar 19, 2026 | 8-K | 2.02, 7.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Mar 2, 2026 | 8-K | 1.02 | Termination of material agreement | — | Filing |
| Feb 27, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Jan 8, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Jan 8, 2026 | 8-K | 2.02, 7.01, 8.01, 9.01 | Results of operations / financial condition; Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Nov 13, 2025 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
SEC-reported company fundamentals
Fundamentals
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
Operating income
$-18.7M
Q2 2026
+17.6% YoY 10-Q filed Aug 12, 2026
Net income
$-18.0M
Q2 2026
+14.5% YoY 10-Q filed Aug 12, 2026
Diluted EPS
$-0.43
Q2 2026
+21.8% YoY 10-Q filed Aug 12, 2026
Operating cash flow
$-35.4M
YTD through Jun 30, 2026
+2.1% YoY 10-Q filed Aug 12, 2026
Free cash flow
$-35.5M
YTD through Jun 30, 2026
+3.3% YoY 10-Q filed Aug 12, 2026
Cash & equivalents
$41.4M
As of Jun 30, 2026
-1.1% YoY 10-Q filed Aug 12, 2026
Assets
$99.1M
As of Jun 30, 2026
-37.5% YoY 10-Q filed Aug 12, 2026
Liabilities
$12.4M
As of Jun 30, 2026
-20.1% YoY 10-Q filed Aug 12, 2026
Stockholders’ equity
$86.7M
As of Jun 30, 2026
-39.4% YoY 10-Q filed Aug 12, 2026
Shares outstanding
42.9M
As of Aug 7, 2026
+36.2% YoY 10-Q filed Aug 12, 2026
Current market context
Price performance
Dated price context from the historical market series already collected for this security.
Recent stored close
$1.83
View live quote ↗
52-week low
$1.27
Mar 30, 2026
52-week high
$3.56
Jan 7, 2026
Below 52-week high
48.6%
1W return
-12.9%
1M return
-6.2%
3M return
+20.4%
6M return
+13.0%
YTD return
-24.1%
1Y return
+21.2%
30-day volatility
74.2%
90-day volatility
69.7%
1Y max drawdown
-57.1%
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
How to read Schedule 13 ownership changes
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.
Beneficial ownership filing history
Showing 3 of 7 filing(s) · 4 older require more history accessView beneficial ownership filing evidence
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Citadel Advisors CIK0001423053 | Mar 31, 2026 observed May 15, 2026 filed · 45d Schedule 13G amendment | Exit below reporting threshold | 13 -1.7M | 0.00% -5.50 pts | $1.39 | $1.77 | $1.87 |
| Citadel Advisors CIK0001423053 | Nov 14, 2025 observed Nov 21, 2025 filed · 7d Initial Schedule 13G | Initial Schedule 13G | 1.7M +180.5K | 5.50% +0.60 pts | $2.24 | $2.30 | $1.87 |
| Citadel Advisors CIK0001423053 | Sep 30, 2025 observed Nov 14, 2025 filed · 45d Schedule 13G amendment | Exit below reporting threshold | 1.5M -354.3K | 4.90% -1.10 pts | $1.81 | $2.24 | $1.87 |
Explore more institutional activity
Related research
Compare ACRV with other securities showing similar institutional activity or recent accumulation across several tracked institutions.